PET/MRI in Patients With Suspected Prostate Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This diagnostic clinical trial will be conducted according to a randomized, prospective,
controlled, double-arm, single-centre design. The control will be implemented by comparing
the PET/MRI results with the histopathological finding after radical prostatectomy (positive
state), the assumed absence of a relevant prostate cancer focus if PET/MRI guided biopsy and
standard biopsy are negative (negative state) and/or the detection of a biochemical tumor
relapse [rising prostate specific antigen (PSA) after PSA nadir; secondary objective].